Van ECK Associates Corp Has $35.61 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Van ECK Associates Corp trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 13.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,615,695 shares of the company's stock after selling 259,692 shares during the quarter. Van ECK Associates Corp owned 0.14% of Teva Pharmaceutical Industries worth $35,610,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of TEVA. Allspring Global Investments Holdings LLC grew its position in Teva Pharmaceutical Industries by 2,018.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after acquiring an additional 1,045,305 shares during the period. Gladstone Institutional Advisory LLC grew its position in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 154,249 shares of the company's stock valued at $3,400,000 after acquiring an additional 10,310 shares during the period. Kestra Private Wealth Services LLC grew its position in Teva Pharmaceutical Industries by 201.7% in the fourth quarter. Kestra Private Wealth Services LLC now owns 31,526 shares of the company's stock valued at $695,000 after acquiring an additional 21,075 shares during the period. WCM Investment Management LLC grew its position in Teva Pharmaceutical Industries by 125.6% in the fourth quarter. WCM Investment Management LLC now owns 135,754 shares of the company's stock valued at $3,030,000 after acquiring an additional 75,584 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its position in Teva Pharmaceutical Industries by 945.7% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 28,850 shares of the company's stock valued at $636,000 after acquiring an additional 26,091 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the company. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Finally, Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.57.

Teva Pharmaceutical Industries Trading Up 2.2 %

Teva Pharmaceutical Industries stock traded up $0.36 during mid-day trading on Tuesday, hitting $16.61. The stock had a trading volume of 8,797,126 shares, compared to its average volume of 12,770,287. The stock has a 50-day simple moving average of $19.93 and a two-hundred day simple moving average of $18.50. The stock has a market capitalization of $18.81 billion, a PE ratio of -11.46, a P/E/G ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company's stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.